Purpose. Based on the assumption that bronchial asthma has certain neurogenic paroxysmal mechanism and links with other paroxysmal diseases - breath-holding spells, epilepsy, migraine and trigeminal neuralgia, we searched antiasthmatic activity of oxcarbazepine and EEG and neural signs frequency during asthma.
Randomized, double-blind, placebo-controlled trial was performed in 46 patients. The EEG (brain-mapping) and neural signs also were searched.

Complete stable remission was achieved in 25 patients (80%) of oxcarbazepine group (n=32) during 3-month trial, when all other antiasthmatic therapy was stopped. Asthma attacks completely disappeared, peak-flow rates increased till normal levels. No improvement was found in patients of placebo group (n=14). Next open-label treatment showed stable efficacy of oxcarbazepine.
EEG and neural signs had 40 patients (87%). No increased convulsive predisposition was found.
. Based on high efficacy of monotherapy by antiepileptic drug and frequency of EEG and neurological signs, we consider bronchial asthma as neurogenic paroxysmal inflammatory disease with complex pathogenic mechanisms, when allergic reactions are only triggers, and initial paroxysmal and inflammatory generator mechanisms of asthma lay in central nervous system. Such diseases also are migraine and trigeminal neuralgia, and in their therapy antiepileptic drugs also are highly effective.